Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment

Evolution, Medicine and Public Health

Volumn 2014, Issue 1, 2014, Pages 18-29

  Ross Gillespie, Adin ^a   Weigert, Michael ^a,b   Brown, Sam P ^c   Kümmerli, Rolf ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY   (Switzerland)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Antivirulence therapy; Experimental evolution; Pseudomonas; Public good quenching; Resistance

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; GALLIUM; GENTAMICIN; IRON; PYOVERDINE; SIDEROPHORE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPOD LARVA; ARTICLE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL VIRULENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXTRACELLULAR QUENCHING; GALLERIA MELLONELLA; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SIDEROPHORE QUENCHING;

EID: 85038628631     PISSN: None     EISSN: 20506201     Source Type: Journal    
DOI: 10.1093/emph/eou003     Document Type: Article

References (61)

1. Pepper JW. Defeating pathogen drug resistance: guidance from evolutionary theory. Evolution 2008;62:3185-91.
2. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 2009;325:1089-93.
3. Allen RC, Popat R, Diggle SP et al. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol, in press.
4. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 2010; 9:117-28.
5. West SA, Diggle SP, Buckling A et al. The social lives of microbes. Annu Rev Ecol Evol Syst 2007;38:53-77.
6. Andre J-B, Godelle B. Multicellular organization in bacteria as a target for drug therapy. Ecol Lett 2005;8:800-10.
7. Mellbye B, Schuster M. The sociomicrobiology of antivirulence drug resistance: a proof of concept. mBio 2011;2:e00131-11.
8. Pepper JW. Drugs that target pathogen public goods are robust against evolved drug resistance. Evol Appl 2012;5: 757-61.
9. Schuster M, Sexton DJ, Diggle SP et al. Acyl-homoserine lactone quorum sensing: from evolution to application. Annu Rev Microbiol 2013;67:43-63.
10. Kalia VC, Purohit HJ. Quenching the quorum sensing system: potential antibacterial drug targets. Crit Rev Microbiol 2011;37:121-40.
11. LaSarre B, Federle MJ. Exploiting quorum sensing to confuse bacterial pathogens. Microbiol Mol Biol Rev 2013;77: 73-111.
12. Defoirdt T, Boon N, Bossier P. Can bacteria evolve resistance to quorum sensing disruption? PLoS Pathog 2010;6: e1000989.
13. Maeda T, Garcia-Contreras R, Pu M et al. Quorum quenching quandary: resistance to antivirulence compounds. ISME J 2012;6:493-501.
14. Garciá-Contreras R, Maeda T, Wood TK. Resistance to quorum-quenching compounds. Appl Environ Microbiol 2013;79:6840-6.
15. Fernández L, Hancock REW. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 2012;25:661-81.
16. Dandekar AA, Chugani S, Greenberg EP. Bacterial quorum sensing and metabolic incentives to cooperate. Science 2012;338:264-6.
17. Miethke M, Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 2007; 71:413-51.
18. Imperi F, Tiburzi F, Visca P. Molecular basis of pyoverdine siderophore recycling in Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2009;106:20440-5.
19. Kaneko Y, Thoendel M, Olakanmi O et al. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 2007;117:877-88.
20. Braud A, Hoegy F, Jezequel K et al. New insights into the metal specificity of the Pseudomonas aeruginosa pyoverdine- iron uptake pathway. Environ Microbiol 2009;11:1079-91.
21. Schalk IJ, Guillon L. Pyoverdine biosynthesis and secretion in Pseudomonas aeruginosa: implications for metal homeostasis. Environ Microbiol 2013;15:1661-73.
22. Hauser AR, Rello J. Severe Infections Caused by Pseudomonas aeruginosa. New York: Springer, 2003.
23. Meyer J-M, Neely A, Stintzi A et al. Pyoverdin is essential for viruence of Pseudomonas aeruginosa. Infect Immun 1996;64:518-23.
24. Takase H, Nitanai H, Hoshino K et al. Impact of siderophore production on Pseudomonas aeruginosa infections in immunosuppressed mice. Infect Immun 2000; 68:1834-9.
25. Banin E, Lozinski A, Brady KM et al. The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent. Proc Natl Acad Sci USA 2008;105: 16761-6.
26. Ghysels B, Thi Min Dieu B, Beatson SA et al. FpvB, an alternative type I ferripyoverdine receptor of Pseudomonas aeruginosa. Microbiology 2004;150:1671-80.
27. Banin E, Vasil ML, Greenberg EP. Iron and Pseudomonas aeruginosa biofilm formation. Proc Natl Acad Sci USA 2005; 102:11076-81.
28. Kümmerli R, Jiricny N, Clarke LS et al. Phenotypic plasticity of a cooperative behaviour in bacteria. J Evol Biol 2009;22: 589-98.
29. Kanj SS, Sexton DJ. Treatment of Pseudomonas aeruginosa infections. In: Basow DS (ed.). UpToDate. Waltham, MA: UpToDate, 2013.
30. Garciá-Contreras R, Lira-Silva E, Jasso-Chávez R et al. Isolation and characterization of gallium resistant Pseudomonas aeruginosa mutants. Int J Med Microbiol 2013;303:574-82.
31. Nadal Jimenez P, Koch G, Thompson JA et al. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol Mol Biol Rev 2012;76:46-65.
32. Reszka KJ, O'Malley Y, McCormick ML et al. Oxidation of pyocyanin, a cytotoxic product from Pseudomonas aeruginosa, by microperoxidase 11 and hydrogen peroxide. Free Radic Biol Med 2004;36:1448-59.
33. Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2013.
34. Kahm M, Hasenbrink G, Lichtenberg-Fraté H et al. grofit: fitting biological growth curves with R. J Stat Softw 2010;33:1-21.
35. Therneau TN, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer, 2000.
36. Bernstein LR. Mechanisms of therapeutic activity for gallium. Pharmacol Rev 1998;50:665-82.
37. Lamont IL, Beare P, Ochsner U et al. Siderophoremediated signaling regulates virulence factor production in Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2002; 99:7072-7.
38. Leoni L, Orsi N, de Lorenzo V et al. Functional analysis of PvdS, an iron starvation sigma factor of Pseudomonas aeruginosa. J Bacteriol 2000;182:1481-91.
39. Jiricny N, Diggle SP, West SA et al. Fitness correlates with the extent of cheating in a bacterium. J Evol Biol 2010;23: 738-47.
40. Racey D, Inglis RF, Harrison F et al. The effect of elevated mutation rates on the evolution of cooperation and virulence of Pseudomonas aeruginosa. Evolution 2010;64: 515-21.
41. Dumas Z, Kümmerli R. Cost of cooperation rules selection for cheats in bacterial metapopulations. J Evol Biol 2012; 25:473-84.
42. Harrison F, Browning LE, Vos M et al. Cooperation and virulence in acute Pseudomonas aeruginosa infections. BMC Biol 2006;4:21.
43. Ross-Gillespie A. Model Socialite, Problem Pathogen: the Evolution and Ecology of Cooperation in the Bacterium Pseudomonas aeruginosa. Institute of Evolutionary Biology. Edinburgh: University of Edinburgh, 2009.
44. Köhler T, Perron GG, Buckling A et al. Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog 2010;6:e1000883.
45. Kümmerli R, Griffin AS, West SA et al. Viscous medium promotes cooperation in the pathogenic bacterium Pseudomonas aeruginosa. Proc R Soc Lond B 2009;276: 3531-8.
46. Ross-Gillespie A, Gardner A, Buckling A et al. Density dependence and cooperation: theory and a test with bacteria. Evolution 2009;63:2315-25.
47. Griffin A, West SA, Buckling A. Cooperation and competition in pathogenic bacteria. Nature 2004;430: 1024-7.
48. Dumas Z, Ross-Gillespie A, Kümmerli R. Switching between apparently redundant iron-uptake mechanisms benefits bacteria in changeable environments. Proc R Soc Lond B 2013;280:20131055.
49. Braud A, Hannauer M, Mislin GLA et al. The Pseudomonas aeruginosa pyochelin-iron uptake pathway and its metal specificity. J Bacteriol 2009;191:3517-25.
50. Poole K, McKay GA. Iron acquisition and its control in Pseudomonas aeruginosa: many roads lead to Rome. Front Biosci 2003;8:d661-86.
51. Evers A, Hancock RD, Martell AE et al. Metal ion recognitionin ligands with negatively charged oxygen donor groups. Complexation of Fe(III), Ga(III), In(III), Al(III), and other highly charged metal ions. Inorg Chem 1989;28:2189-95.
52. Read AF. The evolution of virulence. Trends Microbiol 1994; 2:73-7.
53. Ochsner UA, Johnson Z, Lamont IL et al. Exotoxin A production in Pseudomonas aeruginosa requires the ironregulated pvdS gene encoding an alternative sigma factor. Mol Microbiol 1996;21:1019-28.
54. Wilderman PJ, Vasil AI, Johnson Z et al. Characterization of an endoprotease (PrpL) encoded by a pvdS-regulated gene in Pseudomonas aeruginosa. Infect Immun 2001;69: 5385-94.
55. Garciá-Contreras R, Pérez-Eretza B, Lira-Silva E et al. Gallium induces the production of virulence factors in Pseudomonas aeruginosa. Pathog Dis 2013. DOI: 10.1111/ 2049-632X.12105.
56. Chitambar CR. Gallium-containing anticancer compounds. Future Med Chem 2012;4:1257-72.
57. DeLeon K, Balldin F, Watters C et al. Gallium maltolate treatment eradicates Pseudomonas aeruginosa infection in thermally injured mice. Antimicrob Agents Chemother 2009;53:1331-7.
58. Kelson AB, Carnevali M, Truong-Le V. Galliumbased anti-infectives: targeting microbial iron-uptake mechanisms. Curr Opin Pharmacol 2013;13:707-16.
59. Walsh C. Where will new antibiotics come from? Nat Rev Microbiol 2003;1:65-70.
60. Livermore DM. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011;66:1941-4.
61. Stanton TB. A call for antibiotic alternatives research. Trends Microbiol 2013;21:111-3.